23
total announcements
509079.BO · 15 min delayed
Gufic Biosciences Ltd
Gufic Biosciences Ltd has received an appellate order from the Commissioner of Income Tax (Appeal) allowing its appeal against an income tax demand of Rs. 4,33,36,680 for the Assessment Year 2024-25.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has announced the closure of its trading window for all designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has received an ESG rating of CRISIL ESG 62 (Category: Strong) from Crisil for FY 2025-26, based on publicly available information.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has received a letter from NSE rejecting its waiver application for a penalty of ₹1,72,000 for non-compliance with SEBI regulations regarding the appointment of an independent director without shareholder approval.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has announced the promotion and change in designation of two senior management personnel, Ms. Ami Shah and Mr. Pinak Padhya, effective September 2, 2026.
Gufic Biosciences Ltd
Gufic Biosciences Limited held an earnings conference call on August 17, 2026, to discuss its Q1 FY27 financial results. The company's management team, including CEO Pranav Choksi and CFO Devkinandan Roonghta, presented the results and answered questions from investors. The company reported progress in various areas, including the qualification and validation of its Indore plant, the launch of new products, and the expansion of its therapeutic franchise.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has published a newspaper advertisement regarding a Special Window for re-lodgement of transfer deeds relating to physical securities and dematerialization in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has announced the audio recording of its earnings conference call held on August 17, 2026. The recording is available on the company's website and a written transcript will be submitted later.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has announced unaudited financial results for the quarter ended June 30, 2026, with total comprehensive income of ₹13,271 lakhs and net profit of ₹512 lakhs. The results have been uploaded on the company's website and stock exchanges' websites.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has released an investor presentation for the quarter ended June 30, 2026, highlighting its Indore facility's progress, including the completion of qualification phases, product permissions, and capacity utilization. The company is on track to achieve its targets and is expanding its capabilities to manufacture long-acting depot products and lipid-based antifungals.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has approved the incorporation of a subsidiary in the Philippines and investment by way of subscription to its equity share capital. The proposed subsidiary will undertake marketing, distribution, and other allied activities in the Philippines, facilitating the expansion of the Company's business and presence in the Philippines.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, showing revenue of Rs. 26,122.75 lakhs and net profit of Rs. 2,246.02 lakhs. The company has also announced the incorporation of a subsidiary in the Philippines and investment by way of subscription to the equity share capital of the proposed subsidiary.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of ₹2,246.02 lakhs and a revenue of ₹26,122.75 lakhs. The company has also incorporated a subsidiary in the Philippines and made an investment in the equity share capital of the proposed subsidiary. The board of directors has approved the financial results and the incorporation of the subsidiary.
Gufic Biosciences Ltd
Gufic Biosciences Ltd announces its 42nd Annual General Meeting to be held on September 4, 2026, through video conferencing, with e-voting details provided.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has released its Business Responsibility and Sustainability Report for the Financial Year 2025-26, highlighting its commitment to responsible business practices, governance, and sustainability.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has announced its annual report for the financial year 2025-2026, along with the notice of its 42nd annual general meeting. The company has reported revenue from operations of ₹940.48 crore and EBITDA of ₹137.22 crore for the year 2025-2026.
Gufic Biosciences Ltd
Gufic Biosciences Ltd announces book closure and record date for 42nd Annual General Meeting and payment of final dividend for FY 2025-26.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has announced the 42nd Annual General Meeting (AGM) to be held on September 04, 2026, through video conferencing. The company will consider adopting audited financial statements for the year ended March 31, 2026, and declare a final dividend of 10%.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has scheduled an Earnings Conference Call for investors/analysts on August 17, 2026, at 04:30 p.m. (IST), to discuss the company's business background, prospects, and financial performance.
Gufic Biosciences Ltd
Gufic Biosciences Ltd has informed BSE that a Board meeting is scheduled on August 14, 2026, to consider and approve the Unaudited Financial Results for the quarter ended June 30, 2026.